WE SEE THE FUTURE FIRST

WE SEE THE FUTURE FIRST

Minerva Biotechnologies is focused on cancer and stem cell therapeutics. We are developing cancer immunotherapies targeting 80% of solid tumors and to prevent cancer metastasis

more info
patternframe

Welcome to Minerva Biotechnologies

Exploring the Space between Cancers and Stem Cells

Cancer Therapeutics

Cancer Therapeutics

Minerva's CAR T therapeutics will attack solid tumors that are MUC1* positive. This represents approximately 80% of all cancers.

learn more
Regenerative Medicine

Regenerative Medicine

Minerva’s stem cell discoveries will enable pharmaceutical companies to utilize regenerative medicine in a variety of diseases.

learn more
AlphaSTEM®

AlphaSTEM®

Using AlphaSTEM® iPSC generation is more efficient, cell expansion is faster, and differentiation efficiency is increased.

learn more

We See The Future First.

Dr. Cynthia Bamdad will present next generation cancer immunotherapy at annual meeting of AACR April 16th

featured news

Dr. Cynthia Bamdad will present next generation cancer immunotherapy at annual meeting of AACR April 16th

Dr. Bamdad will show latest data in presentation  “1XX mutations slow CAR T cell signaling and increase  in vivo...

Posted on April 16, 2023

view more DETAILS

Latest News

September 18, 2023

BREAKTHROUGH PRIZE ANNOUNCES 2024 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND...

Life Sciences Carl June  and  Michel Sadelain  were awarded the

June 30, 2023

Monday, August 7, 9:10 AM Dr. Bamdad will present: Phase I/II Trial of MUC1*-Targeting CAR T...

Previous attempts to therapeutically target MUC1 failed because they targeted the

April 16, 2023

Dr. Cynthia Bamdad will present next generation cancer immunotherapy at annual meeting of AACR April 16th

Dr. Bamdad will show latest data in presentation  “1XX mutations slow CAR T

View All News

We See The Future First.

Sign Up For Our Mailing List.